Hybrid Friday Satellite Symposium on R/R DLBCL
Preceding the 65th ASH Annual Meeting and Exposition
Friday, December 8, 2023
3:00 PM – 6:00 PM PT
Food and beverage will be provided
San Diego Convention Center
Room 30, A-E
111 West Harbor Drive
San Diego, CA 92101
Also Available to Virtual Attendees via Online Simulcast
FACULTY
Joshua Brody, MD
Director, Lymphoma Immunotherapy Program
Tisch Cancer Institute at Mount Sinai
Faculty, Icahn Genomics Institute
Icahn School of Medicine at Mount Sinai
Hess Center for Science and Medicine
Mount Sinai Hospital
New York, NY
Lorenzo Falchi, MD
Assistant Attending, Lymphoma Service and Cellular Therapy Service
Memorial Sloan-Kettering Cancer Center
Assistant Professor, Medicine
Weill Cornell Medical College
New York, NY
Lori A. Leslie, MD
Director, Indolent Lymphoma and Chronic Lymphocytic Leukemia
John Theurer Cancer Center
Associate Professor, Medicine
Hackensack Meridian School of Medicine
Hackensack, NJ
In recent years, several novel therapeutic classes for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), including antibody-drug conjugates, CAR T, and most recently, bispecific T-cell engaging antibodies have emerged. During this symposium, a panel of clinical experts will present the latest data on these therapeutic advances. They will also discuss the integration of these treatments in clinical practice while a patient with R/R DLBCL shares key aspects of their therapeutic journey.
PROGRAM AGENDA
Joshua Brody, MD
Joshua Brody, MD
Lori A. Leslie, MD
Lorenzo Falchi, MD
All Faculty and Patient
All Faculty
TARGET AUDIENCE
Hematology, hematology/oncology, oncology clinicians
EDUCATIONAL OBJECTIVES
Upon completion of this activity, participants should be better able to:
- Integrate data on additional novel therapeutic classes when managing patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
- Utilize key evidence on CAR T-cell therapies that target CD19 when selecting treatment for individuals with R/R DLBCL
- Apply available data on bispecific antibodies directed against CD20 and CD3 when personalizing therapy for patients with R/R DLBCL
ACCREDITATION
In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.Physician Continuing Medical Education
RMEI Medical Education, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 2.0 contact hour(s) (0.2 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number JA4008290-0000-23-009-L01-P)
Type of Activity: Knowledge
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hour(s).
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be e-mailed to you within 3 weeks. Physicians who would like to claim American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) points must provide ABIM ID and month/date of birth and score 75% or higher on the post-test. The post-test can be accessed through the QR code labeled “ABIM MOC POINTS” on the program flyer at your seat. MOC points will be submitted to ABIM profiles within 4 to 6 weeks of completion. If you have questions regarding the receipt of your e-mailed certificate, please contact RMEI via e-mail at accreditation@rmei.com.
PROVIDER STATEMENT
This activity is provided by RMEI Medical Education, LLC.
SUPPORTER STATEMENT
This activity is supported by an educational grant from Genmab US, Inc. and AbbVie.
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI will disclose to learners the presence or absence of relevant financial relationships for all persons in control of content before the learner engages in the education.
Americans WIth Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact RMEI prior to the live event at contact@rmei.com.
FEE INFORMATION
There is no fee for this educational activity.
FOLLOW RMEI
Additional educational activities offered by RMEI Medical Education, LLC can be found
at www.RMEI.com or by calling toll-free (866) 770-RMEI.